India Globalization Capital, Inc. (NYSE: IGC) Pioneering New Phytocannabinoid Products
Although legal in 28 states for medicinal use, cannabis is still considered a dangerous substance in much of the country. However, many experts now believe that cannabis is a safe alternative to pharmaceuticals for relieving symptoms related to multiple illnesses. Scientific research shows that phytocannabinoids, cannabinoids that occur naturally in the cannabis plant, are effective at relieving convulsions, seizures, anxiety, nausea, and inflammation. From fighting glaucoma to controlling epileptic seizures and easing pain, scientific research has repeatedly shown the efficacy of medicinal marijuana.
Due to government misclassification of cannabis as a Schedule 1 drug, there has been only marginal progress in the utilization of phytocannabinoids, which hold such promise in disease treatment and pain mitigation. Although many pharmaceutical companies still avoid association with cannabinoids, attitudes are changing, and the medicinal benefits of marijuana are being recognized for their worth.
With changes in the acceptance of medicinal marijuana, some pharmaceutical companies are finally beginning to unpack the myriad of potential benefits phytocannabinoids hold. India Globalization Capital, Inc. (NYSE MKT: IGC) is pioneering such efforts. A multi-faceted company with global experience, India Globalization has a primary focus on developing novel cannabis-based therapies for the treatment of debilitating or life threatening conditions. The company’s current pipeline of patented drugs is focused on large market maladies, including therapeutics for neuropathic pain, human and animal seizures, refractory epilepsy, and eating disorders. Several of the company’s products are scheduled for pre-clinical trials this year.
A transformation is now underway in the medical use of cannabinoids for disease treatment, and India Globalization “believe(s) that the legalization of the cannabis industry will create an explosion in demand for cannabinoid-based pharmaceutical therapies, technology, facilities, and financial services.” With a patent portfolio of cannabinoid-based therapies, the company is well positioned for the quickly arriving time when medical cannabis gains widespread acceptance.
For more information, visit the company’s website at www.IGCinc.us
Please see full disclaimers on the NetworkNewsWire website applicable to all content provided by NNW, wherever published or re-published: http://NNW.fm/Disclaimer
Although legal in 28 states for medicinal use, cannabis is still considered a dangerous substance in much of the country. However, many experts now believe that cannabis is a safe alternative to pharmaceuticals for relieving symptoms related to multiple illnesses. Scientific research shows that phytocannabinoids, cannabinoids that occur naturally in the cannabis plant, are effective at relieving convulsions, seizures, anxiety, nausea, and inflammation. From fighting glaucoma to controlling epileptic seizures and easing pain, scientific research has repeatedly shown the efficacy of medicinal marijuana.
Due to government misclassification of cannabis as a Schedule 1 drug, there has been only marginal progress in the utilization of phytocannabinoids, which hold such promise in disease treatment and pain mitigation. Although many pharmaceutical companies still avoid association with cannabinoids, attitudes are changing, and the medicinal benefits of marijuana are being recognized for their worth.
With changes in the acceptance of medicinal marijuana, some pharmaceutical companies are finally beginning to unpack the myriad of potential benefits phytocannabinoids hold. India Globalization Capital, Inc. (NYSE MKT: IGC) is pioneering such efforts. A multi-faceted company with global experience, India Globalization has a primary focus on developing novel cannabis-based therapies for the treatment of debilitating or life threatening conditions. The company’s current pipeline of patented drugs is focused on large market maladies, including therapeutics for neuropathic pain, human and animal seizures, refractory epilepsy, and eating disorders. Several of the company’s products are scheduled for pre-clinical trials this year.
A transformation is now underway in the medical use of cannabinoids for disease treatment, and India Globalization “believe(s) that the legalization of the cannabis industry will create an explosion in demand for cannabinoid-based pharmaceutical therapies, technology, facilities, and financial services.” With a patent portfolio of cannabinoid-based therapies, the company is well positioned for the quickly arriving time when medical cannabis gains widespread acceptance.
For more information, visit the company’s website at www.IGCinc.us
Please see full disclaimers on the NetworkNewsWire website applicable to all content provided by NNW, wherever published or re-published: http://NNW.fm/Disclaimer
